NEW YORK, Aug.17, 2015 /PRNewswire/ -- Onconova Therapeutics (NASDAQ: ONTX) announced submission of investigational new drug application for pivotal phase 3 trial for IV rigosertib in higher-risk myelodysplastic syndromes Friday. The securities responded positively moving over 30% in early morning trading Friday. Our due diligence has uncovered some interesting information that current and potential shareholders may want to read:
Copy and paste to browser may be required.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.